weight loss

Weight. My weight and bad news from my doc. Join me in losing weight

man falling     dr rybacki fishing You can see it in the fishing picture. I failed. It's the genes, it's the food, it's the exercise, it's not my fault. Bull.

Mysimba (Contrave-Naltexone plus bupropion in the EU) now approved for weight loss

Mysimba for weight loss- It is the name for Contrave (naltrexone and bupropion) in Europe. This drug is the newest weight loss drug and had an unusual release of data. What appears to be shown in early data is that it may have a direct effect/benefit in decreasing risk of heart attack.

Weight loss drug decreases heart attacks? Contrave and early data

 

Members Only: 

 

fireworks A study of 4,500 patients using a new weight loss drug called Contrave (bupriprion and naltrexone) had the expected effect of a weight loss benefit, and the drug was FDA approved. A study of 8,910 people in a follow up study had the weight loss benefit, however; the patients taking Contrave had fewer heart attacks than the people who didn't take it.

There is controversy over this trial and apparent early leaks of data, but the information that patients taking the drug had fewer heart attacks is stunning. Importantly, the researchers doing the study thought the benefit on heart attacks may be a direct effect of the drug combination!

More to follow as always.

Contrave and cardiology--could this newer weight loss drug help your heart too?

food

Members Only: 

food Contrave (bupropion and naltrexone) is apparently unique. The SEC disclosed that the US patent office gave the 371 patent to Orexigen Therapeutics based on an interim look at the LIGHT study. What this means is that Contrave has a claim for having a POSITIVE IMPACT on cardiovascular results (outcomes) beyond (unrelated to) weight loss.

More to come and most probably from the American College of Cardiology meeting in San Diego this month. Regardless, having strength in weight loss AND HEART disease is a true breakthrough in medicines.

Will lorcaserin (Lorquess) survive FDA scrutiny?

dr rybacki looking It's always difficult to predict how the FDA will perceive benefit to risk decisions and lorcaserin (Lorquess) is a singular example of this challenge. On one hand, the FDA has data showing that the medicine does work, while on th

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.